"Interferon-beta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity.
| Descriptor ID |
D016899
|
| MeSH Number(s) |
D12.644.276.374.440.890.275 D12.776.467.374.440.890.275 D23.529.374.440.890.275
|
| Concept/Terms |
Interferon-beta- Interferon-beta
- Interferon beta
- Interferon, Fibroblast
- Fibroblast Interferon
- Interferon, beta
- beta Interferon
- beta-Interferon
beta-1 Interferon- beta-1 Interferon
- beta 1 Interferon
- Interferon-beta1
- Interferon beta1
- Interferon, beta-1
- Interferon, beta 1
|
Below are MeSH descriptors whose meaning is more general than "Interferon-beta".
Below are MeSH descriptors whose meaning is more specific than "Interferon-beta".
This graph shows the total number of publications written about "Interferon-beta" by people in this website by year, and whether "Interferon-beta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 2 | 4 |
| 2009 | 3 | 0 | 3 |
| 2010 | 3 | 0 | 3 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon-beta" by people in Profiles.
-
Tao Y, Zhang X, Markovic-Plese S. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS). J Neuroimmunol. 2016 09 15; 298:181-8.
-
Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S. Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurol. 2015 Nov 11; 15:232.
-
Dwyer MG, Zivadinov R, Markovic-Plese S, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Weinstock-Guttman B, Hayward B, Dangond F. Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. J Neuroimmunol. 2015 Apr 15; 281:44-50.
-
Tao Y, Zhang X, Chopra M, Kim MJ, Buch KR, Kong D, Jin J, Tang Y, Zhu H, Jewells V, Markovic-Plese S. The role of endogenous IFN-ß in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis. J Immunol. 2014 Jun 15; 192(12):5610-7.
-
Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013 Dec 15; 191(12):5867-74.
-
Fernandes-Alnemri T, Kang S, Anderson C, Sagara J, Fitzgerald KA, Alnemri ES. Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome. J Immunol. 2013 Oct 15; 191(8):3995-9.
-
Ramgolam VS, Sha Y, Marcus KL, Choudhary N, Troiani L, Chopra M, Markovic-Plese S. B cells as a therapeutic target for IFN-ß in relapsing-remitting multiple sclerosis. J Immunol. 2011 Apr 01; 186(7):4518-26.
-
Ramgolam VS, Markovic-Plese S. Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis. Endocr Metab Immune Disord Drug Targets. 2010 Jun; 10(2):161-7.
-
Zhang X, Markovic-Plese S. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg. 2010 Sep; 112(7):641-5.
-
O'Brien K, Fitzgerald D, Rostami A, Gran B. The TLR7 agonist, imiquimod, increases IFN-beta production and reduces the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010 Apr 15; 221(1-2):107-11.